OUTLOOK Competitors

Stocks . USA . 
Stock . OUTLOOK THERAPEUTICS INC
OTLK Stock  USD 0.45  0.05  10.00%   
OUTLOOK THERAPEUTICS INC competes with Spruce Biosciences, NRX Pharmaceuticals, Cue Biopharma, Werewolf Therapeutics, and IO Biotech; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing OUTLOOK THERAPEUTICS competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of OUTLOOK THERAPEUTICS to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out OUTLOOK THERAPEUTICS Correlation with its peers.

OUTLOOK THERAPEUTICS vs Medicus Pharma Correlation

Very weak diversification

The correlation between OUTLOOK THERAPEUTICS INC and MDCX is 0.5 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding OUTLOOK THERAPEUTICS INC and MDCX in the same portfolio, assuming nothing else is changed.

Moving against OUTLOOK Stock

  0.77CVX Chevron Corp Earnings Call TomorrowPairCorr
  0.73BA BoeingPairCorr
  0.68ABEV Ambev SA ADR Aggressive PushPairCorr
  0.64INTC IntelPairCorr
  0.56GE GE AerospacePairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.020.4510.36
Details
Intrinsic
Valuation
LowRealHigh
0.020.4310.34
Details
Naive
Forecast
LowNextHigh
0.020.8910.79
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
-0.250.801.85
Details

OUTLOOK THERAPEUTICS Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between OUTLOOK THERAPEUTICS and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of OUTLOOK and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of OUTLOOK THERAPEUTICS INC does not affect the price movement of the other competitor.

High positive correlations

MDCX
+ 0.89
CUE
HOWL
+ 0.87
CUE
MDCX
+ 0.87
IOBT
MDCX
+ 0.86
HOWL
MDCX
+ 0.85
OSTX
CUE
+ 0.84
SPRB
  

High negative correlations

IPSC
- 0.85
IOBT
MDCX
- 0.82
IPSC
IPSC
- 0.71
HOWL
IPSC
- 0.7
OSTX
IPSC
- 0.62
CUE
IPSC
- 0.6
COEP

Risk-Adjusted Indicators

There is a big difference between OUTLOOK Stock performing well and OUTLOOK THERAPEUTICS Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze OUTLOOK THERAPEUTICS's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
SPRB  4.78 (0.30) 0.00  22.66  0.00 
 0.00 
 10.15 
(9.46)
 31.24 
NRXP  4.15 (0.55) 0.00 (0.67) 0.00 
 0.00 
 7.34 
(8.02)
 21.29 
CUE  5.51 (1.01) 0.00 (0.50) 0.00 
 0.00 
 11.11 
(12.50)
 50.98 
HOWL  4.56 (0.77) 0.00 (0.41) 0.00 
 0.00 
 7.69 
(7.63)
 51.90 
IOBT  9.18 (0.40) 0.00 (1.01) 0.00 
 0.00 
 9.84 
(16.22)
 151.49 
OSTX  3.06 (0.50) 0.00 (0.30) 0.00 
 0.00 
 5.49 
(5.81)
 16.39 
COEP  3.21 (0.18) 0.00 (0.08) 0.00 
 0.00 
 7.44 
(6.12)
 22.14 
EQ  6.19  0.29  0.03  0.64  6.72 
(8.19)
 19.26 
(12.50)
 43.07 
IPSC  6.36  2.41  0.30  1.82  5.60 
(8.24)
 13.95 
(10.94)
 55.97 
MDCX  3.65 (1.11) 0.00 (2.61) 0.00 
 0.00 
 6.22 
(8.93)
 21.20 

OUTLOOK THERAPEUTICS Competitive Analysis

The better you understand OUTLOOK THERAPEUTICS competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, OUTLOOK THERAPEUTICS's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across OUTLOOK THERAPEUTICS's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
OTLK SPRB NRXP CUE HOWL IOBT OSTX COEP EQ IPSC
 10.00 
 0.45 
OUTLOOK
 2.78 
 81.90 
Spruce
 5.80 
 2.11 
NRX
 2.70 
 0.36 
Cue
 1.41 
 0.72 
Werewolf
 6.06 
 0.31 
IOBT
 2.82 
 1.38 
OSTX
 0.37 
 13.61 
Coeptis
 1.43 
 1.38 
Equillium
 14.83 
 2.01 
Century
Market Volatility
(90 Days Market Risk)
Out of control
Very steady
Dangerous
Out of control
Out of control
Out of control
Dangerous
Somewhat reliable
Abnormally volatile
Abnormally volatile
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weak
Solid
Odds of Financial Distress
(Probability Of Bankruptcy)
Risky
Small
High
Risky
Risky
Risky
Risky
Low
Small
High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
2.04
9.55
4.58
8.29
5.08
20.94
N/A
0.56
3.98
17.79
Net Asset
18.58 T
45.21 M
3.65 M
32.19 M
126.93 M
67.7 M
5.54 M
8.91 M
25.6 M
353.22 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.23
EBITDA
(67.06 T)
(52.68 M)
(24.04 M)
(37.53 M)
(64.05 M)
(93.2 M)
(6.83 M)
(9.44 M)
(7.57 M)
(111.47 M)
Operating Margin
188.64
-71.0
-17.02
-3.51
N/A
N/A
N/A
-22.53
-5.55
-0.2
Current Valuation
55.37 M
78.34 M
69.54 M
23.14 M
4.16 M
11.15 M
67.66 M
66.61 M
46.79 M
143.83 M
Price To Book
10.19
16.28
2.9
2.69
1.1
26.01
14.04
6.91
2.56
1.31
Retained Earnings
(605.71 T)
(250.27 M)
(278.27 M)
(341.86 M)
(414.59 M)
(359.31 M)
(40.4 M)
(98.23 M)
(193.81 M)
(782.34 M)
Current Asset
4.12 M
N/A
N/A
42.21 M
N/A
N/A
N/A
N/A
60.04 M
N/A
Beta
0.18
3.63
1.62
1.47
0.78
0.5
N/A
-0.5
1.86
1.73
Number Of Employees
17
9
14
41
39
80
4
5
35
140
Shares Outstanding
73.51 M
1.07 M
29.61 M
91.24 M
48.54 M
71.95 M
35.21 M
4.82 M
60.89 M
87.41 M
Cash Flow From Operations
(51.83 T)
(55.96 M)
(10.64 M)
(36.33 M)
(56.19 M)
(82.35 M)
(7.28 M)
(6.65 M)
(19.03 M)
(110.14 M)
Total Debt
247.7 B
2.77 M
6.58 M
8.88 M
37.09 M
1.92 M
6.05 M
1.4 M
384 K
53.83 M
Return On Equity
-0.0365
-1.68
-6.83
-1.95
-1.22
-2.4
-9.14
-3.72
-0.9
-0.14
Return On Asset
-1.77
-0.77
-0.98
-0.62
-0.41
-0.89
-2.25
-0.98
-0.44
-0.0447
Number Of Shares Shorted
4.84 M
61.19 K
3.53 M
1.85 M
2.29 M
3.08 M
623.42 K
426.67 K
1.47 M
807.12 K
Book Value Per Share
-0.6
9.56
-0.93
0.17
0.63
0.013
0.11
1.46
0.51
2.04
Current Liabilities
28.27 M
N/A
N/A
3.38 M
N/A
N/A
N/A
N/A
1.81 M
N/A
Total Asset
18.58 T
45.21 M
3.65 M
32.19 M
126.93 M
67.7 M
5.54 M
8.91 M
25.6 M
353.22 M
Debt To Equity
0.52
0.071
0.016
0.33
0.12
0.013
N/A
1.89
0.29
0.12
Short Ratio
0.38
1.79
3.45
0.96
2.36
2.66
1.36
1.67
1.53
0.28
Target Price
5.38
230.5
36.75
5.0
5.2
2.18
11.49
3.0
2.5
3.5
Shares Owned By Institutions
5.5
41.06
25.14
22.93
41.86
44.61
4.44
3.9
49.1
74.55
Market Capitalization
32.99 M
87.66 M
66.32 M
33.85 M
32.57 M
23.69 M
51.06 M
68.21 M
85.25 M
206.28 M
Price To Earning
-1.24
N/A
N/A
-2.17
0.84
N/A
N/A
N/A
-6.7
86.08
Price To Earnings To Growth
N/A
N/A
N/A
N/A
-0.06
N/A
N/A
N/A
N/A
0.26
Price To Sales
23.34
125.77
274.03
4.77
52.22
N/A
N/A
144.54
19.41
1.82
Net Income
(62.42 T)
(53.04 M)
(25.13 M)
(40.67 M)
(70.52 M)
(95.49 M)
(8.88 M)
(10.88 M)
(8.07 M)
(126.57 M)
Earnings Per Share
-1.79
-84.32
-2.31
-0.41
-1.62
-1.34
-0.81
-6.87
-0.58
-0.32
Shares Owned By Insiders
20.85
9.11
9.77
0.74
5.61
5.15
27.99
13.39
20.9
25.45
Revenue
1.41 T
4.91 M
N/A
9.29 M
1.89 M
N/A
N/A
N/A
41.09 M
6.59 M
Working Capital
(28.43 M)
28.96 M
(18.56 M)
11.45 M
97.89 M
45.47 M
906.22 K
(3.46 M)
18.62 M
64.27 M
Cash And Equivalents
26.02 M
93.3 M
24.55 M
66.13 M
145.71 M
170.12 M
N/A
2.38 M
57.56 M
378.76 M
Cash Per Share
0.12
3.96
0.36
1.87
4.93
5.9
N/A
0.06
1.68
6.43
Gross Profit
(27.12 M)
(36.18 M)
145 K
(28.32 M)
(50.48 M)
(2.59 M)
N/A
173.24 K
4.39 M
7.99 M
Day Typical Price
0.47
82.99
2.14
0.36
0.72
0.32
1.39
13.71
1.37
2.12
Accumulation Distribution
0.1
0.0573
0.0714
15431.35
31917.76
0.0882
29064.73
4433.05
53131.75
240532.0
Market Facilitation Index
0.05
4.93
0.16
N/A
N/A
0.03
N/A
0.0
N/A
N/A
Daily Balance Of Power
(1.00)
(0.47)
(0.81)
(0.50)
0.1429
(0.67)
(0.50)
0.0556
(0.14)
(0.92)
Period Momentum Indicator
(0.05)
(2.34)
(0.13)
(0.01)
0.01
(0.02)
(0.04)
0.05
(0.02)
(0.35)
Rate Of Daily Change
0.9
0.97
0.94
0.97
1.01
0.94
0.97
1.0
0.99
0.85
Day Median Price
0.48
83.54
2.16
0.36
0.72
0.33
1.39
13.76
1.37
2.18
Price Action Indicator
(0.05)
(2.80)
(0.12)
(0.01)
0.01
(0.03)
(0.03)
(0.13)
N/A
(0.35)
Relative Strength Index
33.32
47.15
41.95
42.38
44.05
37.57
39.73
46.23
52.81
60.24
Coefficient Of Variation
(991.53)
(2,115)
(996.06)
(940.92)
(1,085)
(5,425)
(918.25)
(4,278)
2674.15
396.02
Mean Deviation
5.82
4.78
4.15
5.51
4.56
9.18
3.06
3.21
6.19
6.36
Jensen Alpha
(0.83)
(0.30)
(0.55)
(1.01)
(0.77)
(0.40)
(0.50)
(0.18)
0.2925
2.41
Total Risk Alpha
(1.71)
(0.74)
(0.87)
(1.51)
(1.20)
(1.80)
(0.70)
(0.40)
(0.30)
1.78
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.0349
0.3028
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
58.44
64.21
Standard Deviation
9.91
6.21
5.01
8.48
7.29
20.09
3.82
4.18
8.78
9.85
Kurtosis
18.09
0.6202
(0.15)
5.21
12.65
29.64
(0.11)
0.5832
1.36
6.44
Potential Upside
11.32
10.15
7.34
11.11
7.69
9.84
5.49
7.44
19.26
13.95
Treynor Ratio
0.2899
22.66
(0.67)
(0.50)
(0.41)
(1.01)
(0.30)
(0.08)
0.6355
1.82
Maximum Drawdown
73.07
31.24
21.29
50.98
51.9
151.49
16.39
22.14
43.07
55.97
Variance
98.14
38.59
25.14
71.87
53.1
403.52
14.57
17.5
77.03
97.04
Market Risk Adjusted Performance
0.2999
22.67
(0.66)
(0.49)
(0.40)
(1.00)
(0.29)
(0.07)
0.6455
1.83
Risk Adjusted Performance
(0.06)
(0.03)
(0.06)
(0.07)
(0.06)
(0)
(0.07)
(0.01)
0.0363
0.1926
Skewness
(3.22)
0.1628
(0.17)
1.36
(2.27)
4.09
(0.17)
0.4564
0.8838
1.76
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
6.72
5.6
Information Ratio
(0.11)
(0.06)
(0.11)
(0.11)
(0.10)
(0.02)
(0.12)
(0.04)
0.0304
0.2463
Value At Risk
(11.11)
(9.46)
(8.02)
(12.50)
(7.63)
(16.22)
(5.81)
(6.12)
(12.50)
(10.94)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(8.19)
(8.24)
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
7.64
8.01
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
45.11
31.34

OUTLOOK THERAPEUTICS Competition Performance Charts

Five steps to successful analysis of OUTLOOK THERAPEUTICS Competition

OUTLOOK THERAPEUTICS's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by OUTLOOK THERAPEUTICS INC in relation to its competition. OUTLOOK THERAPEUTICS's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of OUTLOOK THERAPEUTICS in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact OUTLOOK THERAPEUTICS's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to OUTLOOK THERAPEUTICS INC, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your OUTLOOK THERAPEUTICS position

In addition to having OUTLOOK THERAPEUTICS in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cars Thematic Idea Now

Cars
Cars Theme
Domestic and international companies involved in manufacturing and serving automobiles and trucks. The Cars theme has 14 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cars Theme or any other thematic opportunities.
View All  Next Launch
When determining whether OUTLOOK THERAPEUTICS INC is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if OUTLOOK Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Outlook Therapeutics Inc Stock. Highlighted below are key reports to facilitate an investment decision about Outlook Therapeutics Inc Stock:
How To Invest In OUTLOOK
Details
Is OUTLOOK Stock a good investment?
Details
What is OUTLOOK THERAPEUTICS's Net Worth?
Details
Top Sectors
View
Check out OUTLOOK THERAPEUTICS Correlation with its peers.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OUTLOOK THERAPEUTICS. Anticipated expansion of OUTLOOK directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive OUTLOOK THERAPEUTICS assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of OUTLOOK THERAPEUTICS INC is measured differently than its book value, which is the value of OUTLOOK that is recorded on the company's balance sheet. Investors also form their own opinion of OUTLOOK THERAPEUTICS's value that differs from its market value or its book value, called intrinsic value, which is OUTLOOK THERAPEUTICS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OUTLOOK THERAPEUTICS's market value can be influenced by many factors that don't directly affect OUTLOOK THERAPEUTICS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between OUTLOOK THERAPEUTICS's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding OUTLOOK THERAPEUTICS should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, OUTLOOK THERAPEUTICS's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY